A Phase 2 interventional study of ENX-102 and Placebo in General Anxiety Disorder, sponsored by Engrail Therapeutics INC. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Engrail Therapeutics INC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Generalized Anxiety Disorder with a site in United Kingdom — 5 open to participants now, 6 under way, 1 of them phase 3. Generalized Anxiety Disorder · United Kingdom.
Among the 15 studies in Generalized Anxiety Disorder with a site in United Kingdom, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 2, and was the 10th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →5 of the 15 studies in Generalized Anxiety Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:
Synendos Therapeutics AG · Sites in United Kingdom
Ages 18–55
Cerina Therapeutics · Sites in United Kingdom
Ages 18+
University of Manchester · Sites in United Kingdom
Ages 18–25 · Healthy volunteers
UCLH/UCL Joint Research Office · Sites in United Kingdom
Ages 18–64
Medical Research Council Cognition and Brain Sciences Unit · Sites in United Kingdom
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 100 across the 12 interventional studies, 120 across the 3 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Engrail Therapeutics INC is the lead sponsor of 8 studies on the registry; none are open to participants now.
Engrail Therapeutics INC has 2 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Generalized Anxiety Disorder with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07478744Synendos Therapeutics AGA Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Generalized Anxiety Disorder with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
ENX-102
Drug: ENX-102
ENX-102
Drug: ENX-102
ENX-102
Drug: ENX-102
Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
Also known as: ENX-102 low-dose, ENX-102 mid-dose, ENX-102 high-dose
Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
Safety and tolerability
• Incidence and severity of treatment-emergent AEs (TEAEs)
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Jun 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ENX-102
Generalized Anxiety Disorder →
Engrail Therapeutics INC